Actively Recruiting
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2024-07-03
140
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells. This clinical study aims to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).
CONDITIONS
Official Title
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years at the time of consent
- Malignant tumors without standard treatment options or with disease progression or intolerance after prior therapy
- Good function of major organs
- Negative pregnancy test within 7 days before first dose and not breastfeeding
- Female and male participants of childbearing potential must agree to use contraception during the study and for 6 months after
- Voluntary participation with signed informed consent and good compliance
You will not qualify if you...
- Hematologic malignancies involving or suspected to involve the central nervous system, or primary CNS lymphoma
- Received any anticancer therapy including surgery, chemotherapy, radiotherapy, immunotherapy, or targeted therapy within 4 weeks before first dose
- Severe or uncontrolled diseases deemed risky by the investigator
- History of drug addiction or substance abuse
- Other concomitant diseases or conditions that the investigator judges pose significant safety risks or affect study completion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Cen
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
Z
ZhiMing Li, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here